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Migraine is a debilitating disorder, characterized by severe headaches contributing to a 
poor quality of life. Approximately 14% of Americans are afflicted with migraine headaches. 
Migraine headache is described as unilateral pulsating pain with or without aura; it can have 
associated photophobia, phonophobia, nausea, vomiting, and inability to carry on with daily 
activities during an acute attack. People with migraine headaches often miss days from work and 
important family events. It is the fifth most common reason for emergency department visits and 
contributes to significant economic burden. Patients with episodic migraine often convert to 
chronic migraine, which is defined as greater than 15 migraine days per month for three 
consecutive months.1 In addition to current acute relief medications such as triptans and non-
steroidal anti-inflammatory drug (NSAIDS), it is imperative to start prophylactic medication 
early. 
 Chronic migraine is a complex disorder that is difficult to manage and would benefit 
from a multimodal approach. Lifestyle modifications and concomitant use of prophylactic 
medications are key in migraine prevention. Patients should keep a headache diary to help 
identify migraine triggers. Avoiding triggers and adapting the following recommendations are 
crucial: adequate sleep, stress relaxation techniques, adequate hydration, regular exercise, timely 
eating regular meals, limiting caffeine and other foods that trigger acute migraines. In addition to 
lifestyle modifications the careful consideration of prophylactic medication is warranted under 
the following circumstances: greater than 15 headache days per month, acute medication overuse 
(greater than 8 days), and failure of acute medications to resolve the headache. Current 
recommendations for chronic migraine prophylaxis are to start patients on a low dose non-
selective beta blocker such as propranolol. Even though beta blockers are the preferred treatment 
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other medications such as tricyclic anti-depressants, anti-epileptic drugs, and onabotulinum toxin 
(Botox) are commonly used due to a high number of patients who that are refractory to first line 
treatment.1 The following is a review of medical literature on patients with chronic migraine and 
the comparison of topiramate with Botox for migraine prophylaxis, and the effect on the number 
of headaches per month, over a 12-week period. 
This is a review of two prophylactic medications for chronic migraine prophylaxis, Botox 
and topiramate. Three articles were selected that reviewed the efficacy of topiramate and 
regarding the effectiveness of Botox. These articles measured quality of life through a Migraine 
Specific Quality of Life Questionnaire.  Inclusion criteria for choosing these articles is as 
follows; articles must be published within the last 15 years, focus must be adults excluding 
pediatric populations, primary focus of the articles is chronic migraines, research studies must 
follow patients for at least 12 weeks.  
TOPIRMATE EFFECTIVENESS 
 Topiramate is an Anti-epileptic medication that has been proven to show improvement in 
chronic migraine symptoms. The following research studies evaluated topiramate efficacy in 
chronic migraine prophylaxis, both studies found that it significantly reduced the severity and 
number of headaches per month. 
 In a randomized double-blind trial conducted by Silberstein et all, topiramate was shown 
to be an efficacious prophylactic agent for chronic migraine prevention when compared to 
placebo. The study evaluated the efficacy of topiramate, in a trial that extended over the course 
of 16 weeks and had a total of 306 patients. Participants were divided into two groups treatment 
and placebo. The treatment group was titrated up to topiramate 100mg daily. The study 
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concluded that topiramate 100mg daily significantly reduced the number of migraine days when 
compared to the placebo group.2 In the treatment group patients reported mild to moderate side 
effects ranging from paresthesia, upper respiratory infection, and fatigue. The placebo group also 
reported similar side effects, the most common were fatigue, nausea, and upper respiratory 
infection. The following study had similar findings in a slightly different chronic migraine 
population group, one that overused abortive treatments such as triptans and NSAIDS. 
Similarly, in the following study topiramate was found to be efficacious in the treatment 
of those with an average of 20 migraine days per month. The study was a small 59 person 
randomized double-blind placebo-controlled trial. At baseline 78% of the participants were 
overusing acute medication. Medication overuse is defined as the use of abortive treatment such 
as triptans or NSAIDS greater than eight days per month. Medication overuse is a major 
contributor to rebound headaches thus, adding to the number of headache days per month in 
these patients.3 All ongoing migraine prophylactic medications in the antiepileptic medication 
class were discontinued. Other prophylactic medications were continued if the patient continued 
to have greater than 15 migraine days per month.  
Topiramate reduced the number of migraines in those with acute medication overuse. 
Topiramate was titrated up to a dose of 100mg over the course of several weeks. At the 
completion of the 16-week trial, topiramate statistically significantly reduced the number of 
migraines per month when compared to the placebo, which increased by one. The most common 
side effect noted in both the treatment and control group was paresthesia which occurred in about 
half of the topiramate group and less than 10% in the placebo group. The Migraine Disability 
Assessment (MIDAS) showed an improvement in quality of life with the use of topiramate; 
however, these results were not statistically significant, due to lack of power with a small sample 
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size.3 Overall, topiramate is tolerated and proven to be an effective means of migraine 
prophylaxis, which significantly reduces the quantity and severity of migraine headaches per 
month.  
BOTOX EFFECTIVENESS 
Botox is a medication that is injected into the muscles and leads to temporary muscle 
paralysis. Although the physiology behind how it prevents migraine headaches is not completely 
understood, the following studies demonstrates it is as an effective means of chronic migraine 
prophylaxis, in patients that have failed oral therapies. The first article was a review of two large 
phase III research studies that evaluated Botox as a prophylactic medication for chronic migraine 
headaches.4 Both studies were randomized controlled trials that evaluated a total of 1384 
participants. Patients received Botox injections every three months for a total of two years. The 
studies had similar findings; Botox is efficacious in decreasing the quantity of migraine 
headaches. The studies also assessed quality of life through several questionnaires. Botox 
improved quality of life in patients with chronic migraine and was generally tolerated. Patients 
reported the following side effects neck pain, muscle weakness, and eye ptosis.4 A similar study 
was done that followed patients for one year had similar findings. 
This was a long-term study that followed patients for a year and was divided into a 
double-blind trial then opened as a non-blinded trial. After the blinded portion of the study 
researchers found that Botox decreased the number of headaches per month and the severity of 
symptoms when compared to placebo. During the open phase of the trial all patients received 
Botox injections every three months. At one year the study concluded that patients in the early 
treatment group were found to have a greater than 50% reduction in migraine days per month.4 
Botox also showed an improvement in quality of life as measured by the quality of life 
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questionnaires. Another long-term trial had similar findings such as decreased number of 
headache days by greater than 50% per month.  
A similar trial was conducted to evaluate the effectiveness of Botox as prophylaxis for 
chronic migraine. This was a long-term study that followed patients for two years. This study 
had a total of 716 participants all of which received Botox injections every three months, for the 
course of the study. Upon completion of the study, patients had a statistically significant 
reduction of greater than 50% in migraine headaches per month.5 The most common side effect 
reported by patients was neck pain. Quality of life was evaluated using questionnaires throughout 
the study. Patients had a significant improvement in quality of life with the use of Botox due to 
the significant reduction in pain and headaches days per month. Now that topiramate and Botox 
have been found to be effective it is important to compare them to determine which is the 
superior option. One key limitation of this study was that it was an open-label trial, researchers 
reported that it would be unethical to have participants on a placebo for two years. 
COMPARISION OF BOTOX AND TOPIRAMATE 
In previous studies, when Botox and topiramate were compared to placebos, they both 
prove to be an effective means of chronic migraine prophylaxis. A small double-blind 
randomized pilot study has been conducted, to determine which of these two prophylactic 
medications is superior. This study was conducted for 6 months and concluded that both 
treatment groups saw a reduction in quantity of headaches per month and improvement in quality 
of life. No statistical significance was found between the two medications. Both medications are 




 In evaluation of the efficacy between Botox and topiramate for prophylaxis of chronic 
migraine, the conclusion was that both medications were of equal effectiveness. Individual 
studies with topiramate and Botox had similar findings that both medications substantially 
reduced the number of migraine days per month and improved quality of life. Only one trial has 
been conducted comparing topiramate and Botox as a treatment for prevention of chronic 
migraine; statistical significance was not found to favor one drug or the other due to small 
sample size. More research studies need to be conducted with a larger population to determine 
which is the best treatment option. It is important to also compare treatment options by 
evaluating the side effect profile, route of administration, and cost to determine the best 
treatment option for patients. Patients have different responses to medication, and one treatment 
may work better for one person and the same treatment may not work well for another patient. 
With chronic migraine prophylaxis it is often a process of trial and error of various prophylactic 
meds until the best treatment is found for that individual patient. During this time, it is also 
important to continue lifestyle changes in addition to pharmacological treatment.  
 Although, neither topiramate or Botox were found to be a superior prophylactic treatment 
in reducing migraine days, practitioners may soon find a better choice. An-Calcitonin gene-
related peptide (CGRP) monoclonal antibodies are a new class of medication that has been found 
to reduce chronic migraine headaches. This new class of medication is now FDA approved for 
prevention of chronic migraine. CGRP antibodies medications such as Eptinezumab work by 
blocking Calcitonin gene related peptides that are released by the trigeminal nerve during an 
acute migraine. In phase three clinical trials, this class of medication was found to significantly 
reduce migraine days by about 15 migraine days per month. Common adverse effects noted in 
the trial are injection site reaction and pain.7 When choosing prophylactic medication for patients 
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with chronic migraine, it is important to consider this new class of medication as a treatment 
option.  
CONCLUSION 
 Chronic migraine headaches are a complex disorder to manage. It is important for 
practitioners to consider prophylactic medication in patients with chronic migraine, those who 
have failed acute treatments, and those with acute medication overuse. Medication overuse as an 
indication for migraine prophylaxis because this can quickly progress from episodic migraine 
headache to chronic migraine headaches.6 Patients were found to have an improvement in quality 
of life with the use of either topiramate or Botox as prophylactic agents. Practitioners can also 
consider the use of CGRP antibodies as prophylaxis for their patients. It is important to also 
consider side effect profiles. Careful consideration needs to be done when using a new 
medication with unknown long-term side effects. Overall, these are all suitable options for the 
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